Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and has a high mortality rate worldwide. Sorafenib is the only systemic treatment demonstrating a statistically significant but modest overall survival benefit. We previously have identified the aurora kinases (AURKs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, You-Liang, Wang, Kai-Hung, Hsieh, Hsing-Pang, Yen, Wan-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781143/
https://www.ncbi.nlm.nih.gov/pubmed/35062934
http://dx.doi.org/10.1186/s12929-022-00788-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781143/
https://www.ncbi.nlm.nih.gov/pubmed/35062934
http://dx.doi.org/10.1186/s12929-022-00788-0

Ejemplares similares